Mainland China, Hong Kong, Macao, and Taiwan Gain Access to the Sputnik V Vaccine
The Russian Direct Investment Fund (RDIF) and TopRidge Pharma (a subsidiary company of Tibet Rhodiola Pharmaceutical Holding) announced an agreement on April 1, 2021, to cooperate on the production of over 100 million Sputnik V vaccine doses per year in China.
Additionally, the new agreement empowers TopRidge Pharma to distribute the Sputnik V vaccine in mainland China, Hong Kong, Macao, and Taiwan, subject to all appropriate regulatory approvals.
To date, the two-dose Sputnik V vaccine has been registered in 58 countries globally.
Kirill Dmitriev, CEO of the RDIF, commented in a press release, “Cooperation with Tibet Rhodiola will help increase production capacities of the Sputnik V in China to provide the necessary amounts and help partners in the country and globally to fight the pandemic."
"China is one of the major production hubs for Sputnik V, and we are ready for increasing the scope of partnership with local producers to meet the rising demand for the Russian vaccine, which has an efficacy of 91.6%."
Sputnik V is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.